Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy

This paper in ClinicoEconomics and Outcomes Research explores the cost-effectiveness of the high-dose trivalent influenza vaccine (TIV-HD) in an Italian context, where influenza remains a critical public health issue. Authors simulate the clinical pathways for influenza-related events for people aged 65+, and consider the implications of their findings for the Italian healthcare system.

Abstract: 

"Purpose: Influenza is a significant public health concern, particularly among the elderly, contributing to high morbidity, hospitalizations, and mortality, in addition to increased economic burden sustained by the Italian National Health Service (SSN). Traditional vaccines, ie, standard-dose trivalent inactivated influenza vaccine (TIV-SD), showed lower immunogenicity and effectiveness in older adults than in younger adults, as a result of the immunosenescence process and increased comorbidities. Enhanced formulations, such as the high-dose trivalent influenza vaccine (TIV-HD), have been introduced to address this gap. This study evaluates the cost-effectiveness of TIV-HD compared to TIV-SD for individuals ≥ 65 years of age in Italy.

Patients and Methods: A cost-effectiveness analysis was performed using a population-based decision-analytic model from the perspective of the SSN, over a one-year time horizon. The model simulated clinical pathways for influenza-related events, including general practitioner visits, emergency department consultations, hospitalizations for cardiorespiratory complications, and mortality. Epidemiological and cost data were sourced from national databases and peer-reviewed literature. Three pricing scenarios were explored. The outcomes included life-years (LYs), quality-adjusted life years (QALYs), and healthcare costs, allowing the calculation of the incremental cost-effectiveness ratio (ICER).

Results: Model-based results showed that TIV-HD is a dominant strategy over TIV-SD, yielding both improved health outcomes (14,070 LYs and 13,678 QALYs) and cost savings in all the pricing scenarios explored. When applied to the Italian elderly population eligible for seasonal influenza vaccination, TIV-HD was estimated to generate overall savings ranging from € 82.3 million and € 135.0 million for the National Health Service, driven by the prevention of approximately 50,000 influenza-related hospitalizations.

Conclusion: This analysis indicates that TIV-HD was associated with improved outcomes and lower overall costs compared with TIV-SD under the modeled assumptions. The enhanced clinical effectiveness combined with significant cost reductions underscores TIV-HD as a cost-effective intervention, contributing to sustainable healthcare management in Italy."

Donatella Panatto, Bellone, M., Castello, L., Zanetta, L. and Piccolo, A. (2026). Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy. ClinicoEconomics and Outcomes Research, [online] 18, pp.1–15. doi:10.2147/CEOR.S588333.